COVID 19 drug discovery special: Antiviral treatments for COVID-19 – the role of CRISPR-Cas13

Victorian researchers have embarked on groundbreaking research to potentially stop COVID-19 from replicating in infected human cells using ­advancements in gene editing. This is a major step towards treatment for COVID-19 and its variants. Join Professor Sharon Lewin, Dr Mohamed Fareh and Dr Wei Zhao for front-row insights into fighting novel viruses into the future.

The treatment landscape for COVID-19 and the need for direct-acting antivirals
Professor Sharon Lewin
Infectious disease expert and inaugural Director, Doherty Institute

CRISPR-Cas13 and impact on SARS-CoV2
Dr Mohamed Fareh, Senior Research Fellow, Peter MacCallum Cancer Centre

Variants, viral replication and CRISPR-Cas13
Dr Wei Zhao
Postdoctoral Research Fellow, Doherty Institute